Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration (“FDA”). The Axonics System is the first rechargeable SNM system approved for sale in the United States, Europe, Canada and Australia.
The FDA approval grants Axonics the right to market its product in the United States for the clinical indication of fecal incontinence. The approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans without the necessity of having the device explanted.
Axonics has an additional pre-market approval (“PMA”) filing currently under review with the FDA for the clinical indications of overactive bladder (urinary urgency incontinence and urinary urgency frequency) as well as urinary retention for which the Company anticipates a determination in the near term.
Raymond W. Cohen, CEO of Axonics, commented, “If we consider the millions of women who are suffering in silence with bladder and bowel dysfunction, we believe the market opportunity for Axonics goes well beyond the existing approximately $650 million of revenue that is currently being generated by the incumbent’s non-rechargeable SNM device. We believe the number of patients seeking SNM treatment will expand dramatically over the next few years given our fuss-free, long-lived, full body MRI-compatible device. In the months prior to FDA approval, we invested significant time and resources in building inventory to support our fully trained, U.S. commercial team which now includes 145 territory managers, clinical support specialists and sales managers strategically located around the country. We plan to begin shipping product to U.S. physicians and hospitals during the fourth quarter of 2019, following the fulfillment of customary, pre-launch regulatory requirements.”
About Sacral Neuromodulation and the Axonics r-SNM System
Sacral neuromodulation is used to treat bladder and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics r-SNM System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. The Axonics r-SNM System offers a long-lived miniaturized neurostimulator that is approximately the size of a USB stick and is qualified to last 15 years in the body as compared to the incumbent’s device which is non-rechargeable and requires patients to undergo a surgical intervention to replace the device every 3 to 5 years. In addition to full body MRI conditional labeling, the Axonics r-SNM System features many differentiating attributes. These include a patented tined lead, user-friendly accessories, a wireless charging system optimized for infrequent charging, a small easy-to-use patient remote control and an intuitive clinician programmer that facilitates lead placement and stimulation programming.
PMA approval process with the U.S. FDA
Determination by the FDA of the safety and effectiveness of the Axonics r-SNM System was supported by the results of a detailed review of technical data, published SNM clinical literature and the ARTISAN-SNM 129-patient pivotal clinical study. ARTISAN-SNM was conducted at 14 centers in the U.S. and five centers in Western Europe and met all primary and secondary endpoints. No serious device-related adverse events were reported. During the review period the FDA conducted two detailed PMA audits of the Axonics quality system and manufacturing. The audits were completed without any negative observations.
Conference Call and Webcast
The Company will host a conference call with the investment community to discuss the FDA approval and recent business developments, on September 9, 2019, at 9:00 a.m. Eastern Time.
Interested parties may access the live call via telephone by dialing (866) 687-5771 (U.S.) or (409) 217-8725 (International) and using passcode 3147028. A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, has developed and is commercializing a novel implantable SNM device for patients with urinary and bowel dysfunction. For more information, visit the Company’s website at www.axonicsmodulation.com
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Matt Clawson, +1-949-370-8500
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innodisk’s New 3D NAND TLC SSD Series Targets Enterprise Workload Applications17.9.2019 15:00:00 CEST | Press release
Engineers at Innodisk, using the latest 3D NAND vertical architecture technology, have delivered stellar performance and blistering speeds in the latest iteration of the company’s new 3D NAND TLC SSD range. The Innodisk 3TS5-P SSD series complies with JESD219 standards complementing endurance workloads at enterprise level in situations where data compression or reduction is carried out for encryption purposes but doesn’t distort the normal internal workings of the SSD. The new 3D NAND TLC SSD series handles increased data storage demands in varied form-factors while maintaining read/write speeds for endurance and is designed for heavy workload applications. As data becomes the core of the IoT era and faster data speeds are required to necessitate reliability, the Innodisk 3D NAND TLC offers 2 drive writes per day (DWPD=2). This offers the potential of higher capacity within a smaller physical space thus lowering the mechanical interference and improving the airflow inside the system ch
Stade Rennais F.C. Sign Edge Analysis Deal with Stats Perform17.9.2019 14:57:00 CEST | Press release
Today, Stats Perform, the revolutionary leader in sports AI and data, announced a deal in French professional football with Stade Rennais F.C. (SRFC) to give the French Ligue 1 club access to Edge Analysis, the most sophisticated football match preparation tool available. With the deal, Stade Rennais can use Edge’s revolutionary AI-based features to objectively analyse team performance by comparing playing styles of teams and individuals, conducting game-changing set play analysis and first-of-its-kind automatic positional-based formation analysis, while instantly linking data with video to vastly accelerate the match preparation process. “Stade Rennais have had an exciting start to their season and appear destined to be a force in Ligue 1 this year and beyond,” Stats Perform Chief Executive Officer Carl Mergele said. “Match preparation is a gruelling task for coaches and analysts, and Edge Analysis provides a huge advantage to streamline the days it usually takes to conduct opponent a
ISACA Combines EuroCACS and CSX Conferences for the First Time in ISACA’s 50th Anniversary Year17.9.2019 14:15:00 CEST | Press release
Digital transformation and emerging technologies are the focus of ISACA’s combined EuroCACS/Cybersecurity Nexus (CSX) conference in Geneva, Switzerland, from 16-18 October 2019, as ISACA continues celebrating its 50th anniversary year. Sessions focused on DevOps, Agile, cryptocurrency, mobile payments, the Internet of Things (IoT), and other hot topics will bring together business technology professionals who lead information systems audit, risk, governance and security functions at their enterprises. Keynote speaker Anders Sorman-Nillson, a global futurist and innovation strategist, will open EuroCACS/CSX, and entrepreneur Jon Duschinsky, who was voted the second-most influential communicator in social innovation, will deliver the closing keynote. Also planned is a general-session panel to mark ISACA’s 50th anniversary in 2019 that features industry experts in innovation and a concurrent general session on “The Weaponisation of the IoT.” Attendees can advance their skills across techn
Andersen Global Expands in Rwanda17.9.2019 13:30:00 CEST | Press release
Andersen Global announced today a collaboration agreement with MRB Attorneys in Rwanda. The addition of the Kigali-based firm marks the 16th country with a presence in Africa for Andersen Global. MRB Attorneys was founded in 2013 by the firm’s five partners, who all have extensive experience in private and public legal consultancy services. Today, MRB’s eleven attorneys advise clients in corporate and commercial law, dispute resolution, energy and infrastructure, and government business and policy, with a heavy emphasis on banking and investment issues. They represent a broad clientele of banks, private and public companies, international organizations, and government agencies. “Andersen Global’s reputation of stewardship and transparency lines up well with what our clients value and have come to expect from us. The synergetic collaboration will be beneficial for our clients and our people,” said Emmanuel Butare, MRB Attorneys’ Managing Partner. “We are excited to work with like-minded
Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment17.9.2019 13:15:00 CEST | Press release
There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers. Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level. Proton therapy key players race for Asia markets Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers inc
CE China 2019: The International Brand Show for Consumer and Home Electronics17.9.2019 13:13:00 CEST | Press release
For the first time, CE China - a global IFA event - is held from 19 to 21 September 2019 in Guangzhou, the heart of China's trade and manufacturing business. The new date in September is perfect for preparation of Singles Day and end of year business in Asia. CE China provides an ideal platform and comprehensive services for consumer electronics and home appliance brands. The show has successfully established partnerships with leading global retailer chains such as Suning and Alibaba’s Tmall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005728/en/ Autonomous driving and new mobility at CE China 2019 CE China 2019 includes Connected Driving and New Energy Vehicles section in its spectrum tackling the trend of autonomous driving. Today, intelligent interconnection is not only a major trend in household appliances and electronic consumer goods, but also key to the automotive industry – bringing consumer electronics, hou